AGC Biologics, AdaptVac partner on COVID-19 vaccine

By The Science Advisory Board staff writers

April 24, 2020 -- AGC Biologics, a contract development and manufacturing organization, and AdaptVac have teamed up to develop a COVID-19 vaccine.

The companies, along with the European Union Horizon 2020-sponsored Prevent-nCoV consortium partners, will use AdaptVac's virus-like particle technology to develop the vaccine. This technology makes ideal scaffolds for displaying vaccine antigens due to their particulate nature and dense repetitive subunit organization, according to the companies.

Clinical trials are expected to begin in late-2020.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.